Vanguard Amends Gilead Sciences Stake, Holds 90.8M Shares

TL;DR

**Vanguard still owns a huge chunk of Gilead, showing long-term confidence.**

AI Summary

The Vanguard Group, a major investment firm, filed an amendment (SC 13G/A) on February 13, 2024, updating its ownership in Gilead Sciences Inc. As of December 29, 2023, Vanguard reported beneficial ownership of 90,880,511 shares of Gilead's Common Stock. This filing indicates a significant, passive stake by Vanguard, which is important for investors as it shows continued institutional confidence in Gilead, a pharmaceutical company (CIK: 0000882095).

Why It Matters

This filing confirms that a major institutional investor, The Vanguard Group, maintains a substantial, passive position in Gilead Sciences, signaling ongoing institutional interest and stability for current and prospective shareholders.

Risk Assessment

Risk Level: low — This filing is routine for large institutional investors and indicates a stable, passive ownership stake, posing minimal risk.

Analyst Insight

Investors should note Vanguard's continued substantial, passive ownership as a sign of long-term institutional confidence in Gilead Sciences, but this filing alone doesn't suggest immediate price catalysts.

Key Numbers

• 90,880,511 — Shares Beneficially Owned (Represents The Vanguard Group's total stake in Gilead Sciences Inc. as of December 29, 2023.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and institutional investor
• Gilead Sciences Inc (company) — subject company, a pharmaceutical firm
• 90,880,511 shares (dollar_amount) — number of shares beneficially owned by Vanguard
• December 29, 2023 (date) — date of event requiring the filing
• February 13, 2024 (date) — filing date of the SC 13G/A

Forward-Looking Statements

• Vanguard will likely maintain a significant, passive stake in Gilead Sciences Inc. throughout 2024. (The Vanguard Group) — high confidence, target: December 31, 2024

FAQ

From the Filing

0001104659-24-021020.txt : 20240213 0001104659-24-021020.hdr.sgml : 20240213 20240213170617 ACCESSION NUMBER: 0001104659-24-021020 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-42340 FILM NUMBER: 24628577 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: VANGUARD GROUP INC CENTRAL INDEX KEY: 0000102909 ORGANIZATION NAME: IRS NUMBER: 231945930 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 BUSINESS PHONE: 6106691000 MAIL ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 SC 13G/A 1 tv01018-gileadsciencesinc.htm SCHEDULE 13G/A gileadsciencesinc SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer:  Gilead Sciences Inc Title of Class of Securities:  Common Stock CUSIP Number:  375558103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on the following page(s))     13G CUSIP No.:  375558103 1.  NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON The Vanguard Group - 23-1945930 2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP A.  B.  X 3.  SEC USE ONLY 4.  CITIZENSHIP OF PLACE OF ORGANIZATION Pennsylvania (For questions 5-8, report the number of shares beneficially owned by each reporting person with:) 5.  SOLE VOTING POWER 0 6.  SHARED VOTING POWER 1,589,556 7.  SOLE DISPOSITIVE POWER 106,303,597 8.  SHARED DISPOSITIVE POWER 5,517,114 9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 111,820,711 10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES N/A 11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.97% 12.  TYPE OF REPORTING PERSON IA     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Act of 1934 Item 1(a) - Name of Issuer: Gilead Sciences Inc Item 1(b) - Address of Issuer's Principal Executive Offices: 333 Lakeside Drive Foster City, CA 94404 Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930 Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355 Item 2(c) – Citizenship: Pennsylvania Item 2(d) - T